Skip to content
← The Index board

Promising · 5.8/10

VK2735 (Viking Therapeutics)

Evidence C · mixed evidence ▲ 14.6% momentum 🥇 First scout open
5.8/ 10

VK2735 is an investigational dual GLP-1 and GIP receptor agonist from Viking Therapeutics that produced about 14.7 percent weight loss at 13 weeks in its peer-reviewed VENTURE Phase 2 injectable trial, per Bays 2026. It scores Neutral because every dataset is 13 weeks or shorter and it is not approved. Read the full breakdown →

The prediction game

Where does VK2735 (Viking Therapeutics) go in 12 months?

Lock a call and say how sure you are. Right and confident earns the most; a leaderboard spot is the prize. No money, no stakes.

The Crowd’s Call

Rising or fading over the next 12 months? Lock your call and find out if you saw it coming.

Your 12-month call on VK2735 (Viking Therapeutics)

New voice here? We send a one-tap verification link so every entry comes from a real person. Signed-in members skip this.

Be the first scout on record for VK2735 (Viking Therapeutics). Permanent credit on this page, plus points when your call resolves.

One call per intervention. It locks the moment you submit (no edits, no cancels) and resolves in 12 months. See the scout leaderboard →

Weigh In

Your input feeds the community signal shown beside my verdict. It informs the board and it never sets the score by itself. How community input works.

Tried it in real life?

Which ring does it deserve?

Same as above — one verification covers all your entries here.

Ring Promising Momentum 14.6% Updated Jul 20, 2026 How the Index ranks →

Verdict by Nick Urban, host of the High Performance Longevity podcast.

For education only, not medical advice. Supplements, peptides, and protocols can interact with medications and conditions. Talk to a qualified clinician before starting anything here.